Armata Common Stock vs Net Tangible Assets Analysis

ARMP Stock

USD 2.40 0.03 1.23%

Armata Pharmaceuticals financial indicator trend analysis is way more than just evaluating Armata Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Armata Pharmaceuticals is a good investment. Please check the relationship between Armata Pharmaceuticals Common Stock and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Common Stock vs Net Tangible Assets

Common Stock vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Armata Pharmaceuticals Common Stock account and Net Tangible Assets. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Armata Pharmaceuticals' Common Stock and Net Tangible Assets is 0.18. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Armata Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Armata Pharmaceuticals' Common Stock and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Armata Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Common Stock i.e., Armata Pharmaceuticals' Common Stock and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Common Stock

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Armata Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Armata Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.As of 07/31/2025, Enterprise Value is likely to grow to about 193.3 M, while Selling General Administrative is likely to drop slightly above 12.5 M.

Armata Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Net Debt	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.88	-0.14	0.77	-0.45	0.96	0.03	0.21	0.62	0.99	0.63	0.13	0.88	0.46	-0.15	0.9	0.96	0.73	0.76	0.3	0.84	0.13	0.62	-0.25	0.16	-0.25
Short Long Term Debt Total	0.88		0.21	0.9	-0.76	0.94	-0.07	0.04	0.38	0.92	0.38	0.09	0.92	0.17	-0.12	0.97	0.94	0.41	0.83	0.16	0.99	0.53	0.5	-0.17	0.05	-0.17
Other Current Liab	-0.14	0.21		0.02	-0.57	-0.03	-0.16	-0.25	-0.17	-0.05	-0.17	-0.03	0.25	-0.85	0.04	0.19	-0.04	-0.46	-0.15	0.01	0.24	0.74	-0.09	-0.07	0.03	-0.07
Total Current Liabilities	0.77	0.9	0.02		-0.69	0.83	-0.09	-0.02	0.31	0.82	0.31	0.1	0.74	0.26	-0.08	0.87	0.84	0.31	0.98	0.19	0.9	0.42	0.19	-0.17	0.04	-0.17
Total Stockholder Equity	-0.45	-0.76	-0.57	-0.69		-0.53	0.32	-0.04	-0.26	-0.51	-0.27	-0.15	-0.79	0.31	-0.09	-0.8	-0.52	-0.06	-0.59	-0.15	-0.76	-0.87	-0.03	0.09	0.0	0.09
Property Plant And Equipment Net	0.96	0.94	-0.03	0.83	-0.53		0.09	0.06	0.46	0.98	0.46	0.07	0.86	0.4	-0.23	0.91	1.0	0.59	0.8	0.14	0.93	0.23	0.67	-0.15	0.05	-0.15
Retained Earnings	0.03	-0.07	-0.16	-0.09	0.32	0.09		-0.29	-0.24	0.02	-0.24	-0.16	-0.15	0.37	-0.97	-0.14	0.08	0.05	-0.08	-0.38	-0.03	-0.27	0.44	0.69	-0.61	0.69
Accounts Payable	0.21	0.04	-0.25	-0.02	-0.04	0.06	-0.29		0.32	0.17	0.32	-0.02	0.22	0.12	0.28	0.16	0.07	0.31	0.02	0.63	0.01	-0.11	0.02	-0.29	0.23	-0.29
Cash	0.62	0.38	-0.17	0.31	-0.26	0.46	-0.24	0.32		0.51	1.0	0.02	0.61	0.26	0.17	0.55	0.46	0.89	0.31	0.29	0.28	-0.05	0.23	-0.36	0.29	-0.36
Non Current Assets Total	0.99	0.92	-0.05	0.82	-0.51	0.98	0.02	0.17	0.51		0.51	0.15	0.88	0.38	-0.16	0.92	0.98	0.61	0.79	0.32	0.9	0.22	0.6	-0.26	0.16	-0.26
Cash And Short Term Investments	0.63	0.38	-0.17	0.31	-0.27	0.46	-0.24	0.32	1.0	0.51		0.02	0.61	0.26	0.17	0.55	0.46	0.89	0.31	0.29	0.28	-0.05	0.23	-0.36	0.28	-0.36
Common Stock Shares Outstanding	0.13	0.09	-0.03	0.1	-0.15	0.07	-0.16	-0.02	0.02	0.15	0.02		0.17	-0.03	0.15	0.16	0.07	-0.01	0.1	0.26	0.09	0.08	-0.1	-0.1	0.09	-0.1
Non Current Liabilities Total	0.88	0.92	0.25	0.74	-0.79	0.86	-0.15	0.22	0.61	0.88	0.61	0.17		0.09	-0.04	0.98	0.86	0.56	0.66	0.29	0.89	0.53	0.49	-0.21	0.12	-0.21
Other Current Assets	0.46	0.17	-0.85	0.26	0.31	0.4	0.37	0.12	0.26	0.38	0.26	-0.03	0.09		-0.32	0.16	0.4	0.63	0.39	-0.14	0.16	-0.48	0.42	0.24	-0.24	0.24
Other Stockholder Equity	-0.15	-0.12	0.04	-0.08	-0.09	-0.23	-0.97	0.28	0.17	-0.16	0.17	0.15	-0.04	-0.32		-0.05	-0.22	-0.07	-0.07	0.36	-0.16	0.07	-0.48	-0.7	0.64	-0.7
Total Liab	0.9	0.97	0.19	0.87	-0.8	0.91	-0.14	0.16	0.55	0.92	0.55	0.16	0.98	0.16	-0.05		0.91	0.52	0.8	0.28	0.94	0.52	0.43	-0.21	0.1	-0.21
Property Plant And Equipment Gross	0.96	0.94	-0.04	0.84	-0.52	1.0	0.08	0.07	0.46	0.98	0.46	0.07	0.86	0.4	-0.22	0.91		0.59	0.81	0.14	0.93	0.22	0.66	-0.15	0.05	-0.15
Total Current Assets	0.73	0.41	-0.46	0.31	-0.06	0.59	0.05	0.31	0.89	0.61	0.89	-0.01	0.56	0.63	-0.07	0.52	0.59		0.36	0.12	0.32	-0.25	0.51	-0.14	0.13	-0.14
Short Term Debt	0.76	0.83	-0.15	0.98	-0.59	0.8	-0.08	0.02	0.31	0.79	0.31	0.1	0.66	0.39	-0.07	0.8	0.81	0.36		0.17	0.83	0.29	0.17	-0.16	0.03	-0.16
Intangible Assets	0.3	0.16	0.01	0.19	-0.15	0.14	-0.38	0.63	0.29	0.32	0.29	0.26	0.29	-0.14	0.36	0.28	0.14	0.12	0.17		0.14	0.04	-0.23	-0.65	0.51	-0.65
Net Debt	0.84	0.99	0.24	0.9	-0.76	0.93	-0.03	0.01	0.28	0.9	0.28	0.09	0.89	0.16	-0.16	0.94	0.93	0.32	0.83	0.14		0.55	0.49	-0.13	0.01	-0.13
Non Currrent Assets Other	0.13	0.53	0.74	0.42	-0.87	0.23	-0.27	-0.11	-0.05	0.22	-0.05	0.08	0.53	-0.48	0.07	0.52	0.22	-0.25	0.29	0.04	0.55		-0.1	0.01	-0.07	0.01
Net Receivables	0.62	0.5	-0.09	0.19	-0.03	0.67	0.44	0.02	0.23	0.6	0.23	-0.1	0.49	0.42	-0.48	0.43	0.66	0.51	0.17	-0.23	0.49	-0.1		0.21	-0.21	0.21
Common Stock Total Equity	-0.25	-0.17	-0.07	-0.17	0.09	-0.15	0.69	-0.29	-0.36	-0.26	-0.36	-0.1	-0.21	0.24	-0.7	-0.21	-0.15	-0.14	-0.16	-0.65	-0.13	0.01	0.21		-0.9	1.0
Short Term Investments	0.16	0.05	0.03	0.04	0.0	0.05	-0.61	0.23	0.29	0.16	0.28	0.09	0.12	-0.24	0.64	0.1	0.05	0.13	0.03	0.51	0.01	-0.07	-0.21	-0.9		-0.9
Common Stock	-0.25	-0.17	-0.07	-0.17	0.09	-0.15	0.69	-0.29	-0.36	-0.26	-0.36	-0.1	-0.21	0.24	-0.7	-0.21	-0.15	-0.14	-0.16	-0.65	-0.13	0.01	0.21	1.0	-0.9

Click cells to compare fundamentals

Armata Pharmaceuticals Account Relationship Matchups

Armata Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	39.5M	69.8M	95.8M	98.4M	86.4M	90.8M
Short Long Term Debt Total	13.2M	38.0M	48.8M	120.4M	126.5M	132.8M
Other Current Liab	3.5M	658K	(10.8M)	5.4M	3.1M	3.3M
Total Current Liabilities	6.7M	4.8M	24.9M	16.5M	48.2M	50.7M
Total Stockholder Equity	18.9M	25.4M	36.1M	(32.1M)	(48.0M)	(45.6M)
Property Plant And Equipment Net	12.8M	38.1M	46.7M	57.3M	54.9M	57.7M
Retained Earnings	(179.7M)	(202.9M)	(239.8M)	(308.8M)	(327.7M)	(344.1M)
Accounts Payable	956K	1.1M	1.7M	1.6M	766K	1.2M
Cash	9.6M	10.3M	14.9M	13.5M	9.3M	11.2M
Non Current Assets Total	28.7M	54.8M	68.8M	79.2M	75.1M	78.9M
Cash And Short Term Investments	9.6M	10.3M	14.9M	13.5M	9.3M	11.3M
Common Stock Shares Outstanding	16.4M	24.1M	34.3M	36.1M	59.1M	62.0M
Liabilities And Stockholders Equity	39.5M	69.8M	95.8M	98.4M	86.4M	90.8M
Non Current Liabilities Total	14.0M	39.6M	34.9M	114.0M	86.2M	90.5M
Other Current Assets	636K	1.7M	15.9M	2.3M	1.3M	2.4M
Other Stockholder Equity	198.4M	228.0M	275.5M	276.4M	279.4M	293.3M
Total Liab	20.7M	44.4M	59.8M	130.4M	134.5M	141.2M
Property Plant And Equipment Gross	12.8M	48.3M	57.8M	69.1M	68.1M	71.5M
Total Current Assets	10.8M	15.0M	27.0M	19.2M	11.3M	11.0M
Short Term Debt	2.3M	3.0M	34.0M	9.5M	47.8M	50.2M
Net Debt	3.5M	27.7M	34.0M	106.8M	117.2M	123.1M
Non Currrent Assets Other	(2.1M)	(8.3M)	(9.6M)	8.2M	6.5M	6.8M
Common Stock Total Equity	99K	187K	271K	361K	324.9K	308.7K
Common Stock	99K	187K	271K	361K	362K	343.9K
Capital Surpluse	172.0M	198.4M	228.0M	275.5M	247.9M	245.6M
Property Plant Equipment	4.2M	12.8M	2.2M	3.6M	4.2M	4.4M
Net Tangible Assets	11.1M	15.4M	11.7M	22.3M	25.7M	17.0M
Other Assets	(1K)	23.1M	13.2M	18.6M	21.4M	22.5M
Net Invested Capital	19.6M	25.4M	36.1M	50.2M	46.4M	28.7M
Net Working Capital	4.1M	10.2M	2.2M	2.7M	(36.9M)	(35.1M)

Pair Trading with Armata Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Armata Stock

0.62	A	Agilent Technologies Earnings Call Today	Pair Corr
0.63	JNJ	Johnson Johnson	Pair Corr

Moving against Armata Stock

0.6	TOVX	Theriva Biologics	Pair Corr
0.58	ERNA	Eterna Therapeutics	Pair Corr
0.58	TELO	Telomir Pharmaceuticals,	Pair Corr
0.51	MOLN	Molecular Partners	Pair Corr
0.49	CLOV	Clover Health Investments Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.

The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC